Proteome Sciences PLC (PRM)

Industry Diagnostics & Research

This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

3.50p

Buy

3.90p

arrow-up0.64p (+19.63%)

Proteome Sciences PLC is protein biomarker research and development. The company uses high sensitivity proprietary techniques to detect and characterize differentially expressed proteins in diseases for prognostic and therapeutic applications.
Prices updated at 16 May 2025, 16:35 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Sector
Healthcare
Industry
Diagnostics & Research
Chairman
Mr. Christopher Donovan James Pearce
CEO
-
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
31
Head office
Downside Bridge Road
Cobham
United Kingdom
KT11 3EP
mobile
+44 2070432116
letter
helpdesk@proteomics.com

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Roger Steven McDowell
Non-Executive Director
---0.04m-
Mr. Martin Henry Diggle
Non-Executive Director
-----
Dr. Ian Pike
Executive Director, Chief Scientific Officer
-----
Mr. Richard Paul Dennis
Executive Director, Chief Commercial Officer
-----
Mr. Christopher Donovan James Pearce
Executive Director, Chairman
---0.06m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
No data

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
No data
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.